SV
Contact us
Skärmavbild 2026-09-11 kl. 16.34.30

We invest in the future of life science

KDventures is a listed investment company that invests in innovative pharmaceutical, biotech and medical technology companies with the potential to change how diseases are prevented and treated.

Our portfolio
About us
KDventures as an investment

KDventures at a glance

  • 0,89

    Net asset value per share in SEK, 30 June 2026

  • 677

    Net asset value in MSEK, 30 June 2026

  • 10

    portfolio companies

  • 13

    exits

  • 9

    IPOs

We develop companies through active ownership

We combine specialist expertise in life science with experience in company building, financing and transactions to support portfolio companies on the path to the next value-creating milestone.

Employees
constantin-wenning-idDvA4jPBO8-unsplash

We work actively together with our portfolio companies and contribute experience in strategy, corporate governance and development. The goal is to create the right conditions for long-term value creation.

What is life science?
ohlamour-studio-QLQLg6bSo6s-kd-ventures

We invest in innovative pharmaceutical, biotech and medical technology companies where scientific and clinical advances can create significant value.

Our investment philosophy
national-cancer-institute-OYlhHhzksuk-kd-ventures

We focus our resources on companies with clear value drivers, such as clinical trial results, partnerships, financing and commercial opportunities.

web-images-CxWU7dDKGH0-kd-ventures

Specialist expertise for a complex industry

Investing in life science requires an understanding of science, clinical development, financing and commercialisation. KDventures combines this specialist expertise with active ownership and a diversified portfolio.

Get in touch

Innovation that can create real value

Our portfolio consists of innovative life science companies with the potential to address major medical needs and create significant value if successful.

bioarctic-history-2006

BioArctic: from early-stage biotech to global Alzheimer’s innovation

KDventures was an early investor in BioArctic and supported the company during its formative years. The investment developed into one of KDventures’ most successful exits, where the value of the holding at BioArctic’s IPO corresponded to approximately 80 times the invested capital. Today, BioArctic is an internationally established biotech company and the originator of lecanemab, marketed as Leqembi for the treatment of Alzheimer’s disease.

FIRST INVESTMENT 2005
INVESTED CAPITAL 0.6 MSEK
Read case study
Annan bild Anacardio

AnaCardio: from company formation to clinical proof-of-concept

KDventures co-founded AnaCardio to translate groundbreaking research into a new treatment for heart failure. Since its inception, KDventures has supported the company through financing, company building and clinical development. In 2026, AnaCardio reported positive results from its phase 1b/2a study with AC01, providing clinical proof-of-concept and support for continued development towards phase 2b.

KDVENTURES ROLE Co-founder
CLINICAL PHASE Phase 1b/2a completed
Read case study
christian-bowen-I0ItPtIsVEE-unsplash

Dilafor: from Swedish research to global phase 3 development

KDventures has supported Dilafor through several stages of the company’s development, from early scientific innovation to clinical validation and international partnership. Today, tafoxiparin is being further developed together with the global women’s health company Exeltis, which contributes the industrial capacity and financing required ahead of the planned phase 3 programme.

DEVELOPMENT PHASE Preparations ahead of phase 3
GLOBAL PARTNER Exeltis
Read case study

Upcoming milestones

The information is based on the most recently published data and may change as the companies develop.

Our portfolio
H2 2026

Umecrine Cognition

Study results

Results from the clinical phase 2 study of golexanolone in PBC
H2 2026

Modus Therapeutics

Study results

Topline results from the phase 2a study of sevuparin in CKD-related anaemia
H2 2026

Dilafor

Clinical development

Planned start of the global phase 3 programme with tafoxiparin
Our portfolio

Our latest press releases

See all press releases

KDventures portfolio company Umecrine Cognition invited to showcase Parkinson’s disease program and new translational data at The Michael J. Fox Foundation’s PDTC 2026

KDventures’ portfolio company AnaCardio raises EUR 62.5 million in Series B financing

KDventures’ portfolio company Umecrine Cognition reports last patient out in Phase 1b/2a study evaluating golexanolone in primary biliary cholangitis

KDventures’ portfolio company Umecrine Cognition receives two Notices of Allowance in the US for second-generation GAMSA compounds

The share (KDventures B) ()

SEK
Performance
Go to share data

Summary

The company’s objective is to develop promising medical innovations originating from academic research at Karolinska Institutet and other universities in the Nordic region. The company’s portfolio includes businesses in sectors such as biotechnology and medical technology.

Cookies

This website uses cookiesfor statistics and user experience.

This website uses cookies to improve your user experience, to provide a basis for improvement and further development of the website and to be able to direct more relevant offers to you.

Feel free to read our privacy policy. If you agree to our use, choose Allow all. If you want to change your choice afterwards, you will find that option at the bottom of the page.